ProCE Banner Activity

Adopting Strategies to Eliminate HCV in Persons Who Inject Drugs

Clinical Thought
Eliminating HCV infection among persons who inject drugs is a daunting task whether tackling it from a patient care perspective, through practice transformation, or by influencing policies that improve access to treatment. Nonetheless, there are practical steps that can be taken by clinicians to improve the HCV continuum of care for this challenging population. Here’s my take on some of those steps.

Released: January 19, 2018

Expiration: January 18, 2019

No longer available for credit.

Share

Faculty

Frederick L. Locke

Frederick L. Locke, MD

Co-Leader, Moffitt Immuno-Oncology Program
Vice Chair and Associate Member
Department of Blood and Marrow Transplant and Cellular Immunotherapy
Research Director
Medical Director

Immune Cell Therapy Program
Blood and Marrow Transplant and Cellular Immunotherapy
Moffitt Cancer Center
Tampa, Florida

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

Gilead

Faculty Disclosure

Primary Author

Frederick L. Locke, MD

Co-Leader, Moffitt Immuno-Oncology Program
Vice Chair and Associate Member
Department of Blood and Marrow Transplant and Cellular Immunotherapy
Research Director
Medical Director

Immune Cell Therapy Program
Blood and Marrow Transplant and Cellular Immunotherapy
Moffitt Cancer Center
Tampa, Florida

Frederick L. Altice, MD, has disclosed that he has received consulting fees from Gilead Sciences, LSU, Melinta, and Merck; fees for non-CME/CE services from Bristol-Myers Squibb and Gilead Sciences; and funds for research support from Gilead Sciences.